SARS-CoV-2 vaccination induces immunological memory able to cross-recognize variants from Alpha to Omicron

We address whether T cell responses induced by different vaccine platforms (mRNA-1273, BNT162b2, Ad26.COV2.S, NVX-CoV2373) cross-recognize SARS-CoV-2 variants. Preservation of at least 83% and 85% for CD4+ and CD8+ T cell responses was found, respectively, regardless of vaccine platform or variants analyzed. By contrast, highly significant decreases were observed for memory B cell and neutralizing antibody recognition of variants. Bioinformatic analyses showed full conservation of 91% and 94% of class II and class I spike epitopes. For Omicron, 72% of class II and 86% of class I epitopes were fully conserved, and 84% and 85% of CD4+ and CD8+ T cell responses were preserved. In-depth epitope repertoire analysis showed a median of 11 and 10 spike epitopes recognized by CD4+ and CD8+ T cells from vaccinees. Functional preservation of the majority of the T cell responses may play an important role as a second-level defense against diverse variants.

[1]  J. Mascola,et al.  Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung , 2021, Cell.

[2]  A. Telenti,et al.  Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift , 2021, Nature.

[3]  S. Weaver,et al.  Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection , 2021, bioRxiv.

[4]  A. Meola,et al.  Immune escape of SARS-CoV-2 Omicron variant from mRNA vaccination-elicited RBD-specific memory B cells , 2021, bioRxiv.

[5]  T. de Oliveira,et al.  Escape from recognition of SARS-CoV-2 Beta variant spike epitopes but overall preservation of T cell immunity , 2021, Science Translational Medicine.

[6]  H. van Bakel,et al.  Activity of convalescent and vaccine serum against a B.1.1.529 variant SARS-CoV-2 isolate , 2021, medRxiv.

[7]  C. Siegrist,et al.  Omicron-specific cytotoxic T-cell responses are boosted following a third dose of mRNA COVID-19 vaccine in anti-CD20-treated multiple sclerosis patients , 2021, medRxiv.

[8]  J. Mascola,et al.  Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization , 2021, medRxiv.

[9]  P. Maes,et al.  Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization , 2021, bioRxiv.

[10]  Liyuan Liu,et al.  Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 , 2021, Nature.

[11]  Christina C. Chang,et al.  mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant , 2021, medRxiv.

[12]  M. Nussenzweig,et al.  Plasma neutralization properties of the SARS-CoV-2 Omicron variant , 2021, medRxiv.

[13]  A. Sigal,et al.  SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection , 2021, medRxiv.

[14]  S. Karim,et al.  Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic , 2021, The Lancet.

[15]  E. Callaway.  Beyond Omicron: what’s next for COVID’s viral evolution , 2021, Nature.

[16]  A. Sette,et al.  Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine , 2021, Frontiers in Immunology.

[17]  A. Kaneda,et al.  Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum , 2021, The New England journal of medicine.

[18]  L. Madoff,et al.  Immune Responses in Fully Vaccinated Individuals Following Breakthrough Infection with the SARS-CoV-2 Delta Variant in Provincetown, Massachusetts , 2021, medRxiv.

[19]  A. Sette,et al.  Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells , 2021, Science.

[20]  S. Bhatt,et al.  SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion , 2021, Nature.

[21]  A. Meola,et al.  mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants , 2021, Immunity.

[22]  C. Chakraborty,et al.  Evolution, Mode of Transmission, and Mutational Landscape of Newly Emerging SARS-CoV-2 Variants , 2021, mBio.

[23]  Aaron M. Rosenfeld,et al.  mRNA Vaccination Induces Durable Immune Memory to SARS-CoV-2 with Continued Evolution to Variants of Concern , 2021, bioRxiv.

[24]  M. Nussenzweig,et al.  Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination , 2021, Nature.

[25]  S. Richardson,et al.  Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner , 2021, Cell Host & Microbe.

[26]  R. Scheuermann,et al.  Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals , 2021, Cell Reports Medicine.

[27]  J. Dushoff,et al.  The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic , 2021, Current Biology.

[28]  T. de Oliveira,et al.  Loss of recognition of SARS-CoV-2 B.1.351 variant spike epitopes but overall preservation of T cell immunity , 2021, medRxiv.

[29]  William T. Harvey,et al.  SARS-CoV-2 variants, spike mutations and immune escape , 2021, Nature Reviews Microbiology.

[30]  M. Koopmans,et al.  SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients , 2021, Science Immunology.

[31]  L. Stamatatos,et al.  mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection , 2021, Science.

[32]  R. Walensky,et al.  SARS-CoV-2 Variants of Concern in the United States-Challenges and Opportunities. , 2021, JAMA.

[33]  L. Stamatatos,et al.  A single mRNA immunization boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection , 2021, medRxiv : the preprint server for health sciences.

[34]  Gavin J. D. Smith,et al.  Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients , 2021, Cell Reports.

[35]  A. Sette,et al.  Adaptive immunity to SARS-CoV-2 and COVID-19 , 2021, Cell.

[36]  Bjoern Peters,et al.  Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.

[37]  S. Mallal,et al.  Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases , 2020, bioRxiv.

[38]  Bjoern Peters,et al.  Immunological memory to SARS-CoV-2 assessed for up to eight months after infection , 2020, bioRxiv.

[39]  J. Greenbaum,et al.  Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity , 2020, Cell.

[40]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[41]  Morten Nielsen,et al.  NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data , 2020, Nucleic Acids Res..

[42]  Morten Nielsen,et al.  IEDB-AR: immune epitope database—analysis resource in 2019 , 2019, Nucleic Acids Res..

[43]  Alessandro Sette,et al.  The Immune Epitope Database (IEDB): 2018 update , 2018, Nucleic Acids Res..

[44]  Bjoern Peters,et al.  Experimental validation of the RATE tool for inferring HLA restrictions of T cell epitopes , 2017, BMC Immunology.